Results 191 to 200 of about 1,532,463 (338)

Is there a role for cannabidiol in obesity, metabolic syndrome and binge eating?

British Journal of Pharmacology, EarlyView.
Cannabidiol (CBD) is one of the most abundant phytocannabinoids isolated from the Cannabis sativa plant. CBD is a lipophilic, non‐intoxicating substance that differently from Δ9‐tetrahydrocannabinol (Δ9‐THC) does not present the typical profile of a drug of abuse.
Luca Botticelli, Emanuela Micioni Di Bonaventura, Giacomo Einaudi, Gustavo Provensi, Alessia Costa, Claudio D'Addario, Carlo Cifani, Maria Vittoria Micioni Di Bonaventura   +7 more
wiley   +1 more source

Pharmacotherapy for Cannabis Use Disorder: Preclinical and Clinical Models. [PDF]

Curr Top Behav Neurosci
Bedillion MF, Moore CF, Weerts EM, Arout CA, Harris HM, Haney M.   +5 more
europepmc   +1 more source

Novel approaches for drug development against chronic primary pain: A systematic review

British Journal of Pharmacology, EarlyView.
Abstract Chronic primary pain (CPP) persisting for more than 3 months, associated with significant emotional distress without any known underlying cause, is an unmet medical need. Traditional or adjuvant analgesics do not provide satisfactory pain relief for a great proportion of these patients.
Valéria Tékus, Éva Borbély, Andreas Goebel, Ralf Baron, Zsófia Hajna, Zsuzsanna Helyes   +5 more
wiley   +1 more source

Nationwide outcomes of cardiac surgery in patients with cannabis use disorder. [PDF]

J Cardiothorac Surg
Dewan KC, Mahboubi R, Xu S, Maigrot JA, An C, Zhou G, Ferre JLD, Koroukian SM, Weiss AJ, Soltesz EG.   +9 more
europepmc   +1 more source

5‐HT2A receptor agonism by tert‐leucinamide and valinamide synthetic cannabinoids: In vitro and in vivo evidence

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose New synthetic cannabinoid receptor agonists (SCRAs) are associated with severe adverse effects, including unexpected psychiatric symptoms. These compounds are mainly active through their potent agonism on the cannabinoid receptors CB1 and CB2.
Giorgia Corli, Deborah Rudin, Dino Luethi, Matthias E. Liechti, Sabrine Bilel, Matteo Marti, Henrik Green, Manuela Carla Monti, Caitlyn Norman   +8 more
wiley   +1 more source

Psychiatrists' opinions about non-medicalization of cannabis use disorder in Iran. [PDF]

Discov Ment Health
Namazi H, Sayyah M.
europepmc   +1 more source

Cumulative effect of multiple health and social factors on adolescent mental well‐being: a cross‐sectional study in Catalonia

Child and Adolescent Mental Health, EarlyView.
Background While numerous studies have explored factors contributing to poor mental health, few have examined the combined influence of multiple health and social factors and their cumulative effect. This study specifically aimed to analyze the cumulative effect of multiple health and social factors associated with poor mental well‐being in school‐aged
Marina Robles‐Muñoz, Marina Bosque‐Prous, Cinta Folch, Helena González‐Casals, Gemma Drou‐Roget, Cristina Torrado‐Cortés, Carles Muntaner, Albert Espelt   +7 more
wiley   +1 more source

Trends in cannabis use disorder and treatment by race and ethnicity, 2002-2019. [PDF]

Front Psychiatry
Triguero Roura M, Vora A, Eschliman EL, Mauro PM.   +3 more
europepmc   +1 more source

Parents With Substance Use Disorder in the Holding Tight Treatment System: Intervention Effectiveness and Moderating Effects

Child &Family Social Work, EarlyView.
ABSTRACT Parents with substance use disorder have multiple risks affecting their parenting. Mental health problems and adverse childhood experiences (ACEs) with problems in emotion regulation and adult attachment insecurity may impair the early interaction with the infant.
Saara J. Salo, Marjo Flykt, Yan Li, Mirjam Kalland, Marjukka Pajulo   +4 more
wiley   +1 more source

Considerations for Neural Cannabis Cue-Reactivity Studies in Individuals With Cannabis Use Disorder. [PDF]

Biol Psychiatry Glob Open Sci
Grodin EN, McManus K.
europepmc   +1 more source